Tonix Pharmaceuticals Holding Corp.: management transactions · United States · SEC (Form 4)

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a U.S.-based biopharmaceutical company in the United States that has evolved from a clinical-stage developer into a company with a commercial product and a broader pipeline. Its principal executive offices are in Berkeley Heights, New Jersey. The company was incorporated in 2007 as Tamandare Explorations Inc. and changed its name to Tonix Pharmaceuticals Holding Corp. in 2011. Tonix’s roots are closely tied to the work of Dr. Seth Lederman, who founded the underlying Tonix Pharmaceuticals entity in 2007 and has been a central figure in the company’s development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/tnxp-10k_123125.htm?utm_source=openai)) Tonix’s business model spans several therapeutic areas. The most important near-term asset is TONMYA® (cyclobenzaprine HCl sublingual tablets), which the FDA approved in August 2025 for the treatment of fibromyalgia in adults, followed by a U.S. commercial launch in November 2025. Tonix positions TONMYA as the first new FDA-approved treatment for fibromyalgia in more than 15 years, giving the company a meaningful differentiated entry point in a market with limited treatment alternatives. Beyond that commercial franchise, Tonix maintains a pipeline across pain, psychiatry, infectious disease and rare disease, including TNX-102 SL for major depressive disorder, TNX-1500 in transplant/immunology, TNX-2900 for Prader-Willi syndrome, and TNX-4800 for seasonal prevention of Lyme disease. ([ir.tonixpharma.com](https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of?utm_source=openai)) From a competitive standpoint, Tonix remains a small-cap biotech rather than a large diversified pharmaceutical company. Its investment case is therefore less about scale and more about regulatory and clinical execution, intellectual property, and the commercial potential of a first-in-category or first-in-indication product. The company also appears to be broadening its operational footprint, with offices in Berkeley Heights, New Jersey, plus additional locations in Fort Worth, Montreal and Dublin, and an R&D center in Frederick, Maryland. That footprint suggests a company building out both commercialization and research capabilities. ([tonixpharma.com](https://www.tonixpharma.com/contact/?utm_source=openai)) Recent milestones have been dominated by product launch and pipeline progress. In 2025, Tonix secured FDA approval for TONMYA and then moved into commercial availability. In 2026, it reported publications supporting the product’s pharmacokinetic profile, expanded payer coverage, and continued advancing clinical programs, including TNX-1500 and TNX-2900. For investors, TNXP is best viewed as a NASDAQ-listed U.S. biotech with a near-term commercial catalyst in TONMYA and a pipeline that could create additional optionality if clinical and regulatory execution stays on track. ([ir.tonixpharma.com](https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of?utm_source=openai))